AeroVironment After Earnings: Buy the Dip, Sell the Hype, or Wait?

Hold after earnings, but look for proof before buying more

AVAV still looks like a strong operating business, but the stock remains a "show me" name. In the latest quarter, revenue more than doubled to $642 million and funded backlog rose 65% to $1.2 billion. Shares reacted aggressively, jumping nearly 19% after the beat. The harder question now is whether that backlog can turn into steady revenue and cleaner profits soon enough to justify the valuation.

The recent pullback says the market wants execution

AVAV is down 43.6% over the past month and down 64.9% year to date. That tells you investors are no longer paying purely for excitement around defense drones and backlog growth. They want proof that orders are converting into revenue and earnings without prolonged margin pressure. For current holders, that still looks like a hold. For new buyers, it looks more like a wait-for-confirmation setup.

The long-term case still rests on real demand

Management's fiscal 2030 target keeps the story alive

Even after the pullback, this is still a company management says could grow from roughly $2 billion in fiscal 2026 to $3.5 billion to $4 billion by fiscal 2030. That target matters because it implies AVAV could evolve from a niche drone maker into a broader defense capabilities platform if it keeps adding adjacent products and services.

Revenue is broadening beyond the core drone business

The latest quarter still showed the core engine was real, with autonomous systems revenue of $492 million. The mix is also broadening. In fiscal Q2, BlueHalo contributed $245.1 million of revenue, helping lift total revenue to a record $472.5 million. That does not eliminate execution risk, but it does reduce dependence on a single product line.

Recent demand metrics also support that view. In fiscal Q2, AVAV reported bookings of $1.4 billion and a 2.9 book-to-bill ratio. In the third quarter, management reported first nine months bookings of $2.1 billion and a record funded backlog of $1.1 billion. When order flow stays ahead of revenue, there is usually more room to smooth earnings over the next few quarters.

New capability areas could widen the opportunity

Management has also pointed to significant contract wins over the next 12 to 24 months, while highlighting growing interest in products such as LOCUST. That suggests AVAV is not just selling more unmanned systems; it is also expanding into adjacent areas such as directed energy and counter-UAS solutions.

Why the stock still carries a lot of execution risk

Investors are focused on the path, not just the destination

The selloff is less about whether demand exists and more about how difficult the growth path looks. Market coverage centered on the fiscal 2030 target of $3.5 billion to $4 billion and asked whether the near-term growth curve is steep enough to support that end-state without a heavily back-ended acceleration. That is why valuation multiples have become so important: when a target is ambitious, investors usually demand clearer proof in the next few quarters.

Heavy investment can delay the payoff

Management said fiscal 2027 will require capital spending of 12% to 14% of revenue to expand manufacturing. That is consistent with scaling production, but it also raises the risk that margins stay under pressure while working capital and operating costs rise first. That helps explain why the next earnings report matters: investors want to see whether rising demand continues while the company shows progress on profitability and execution.

The debate now is execution, not demand

Bears also point to competitive pressure and potential risks from M&A activities, alongside regulatory uncertainty. Bulls argue that demand still looks durable and the product portfolio is widening. Even with those concerns visible, analyst sentiment still leans positive, with a Buy consensus rating in coverage cited by Public.com.

What would change the call from hold to buy?

For now, the cleaner stance is still hold. A buy case gets stronger only if the next few quarters show: - backlog converting into revenue more smoothly - margin pressure easing rather than worsening - capacity investment starting to show up in reported results

Until then, AVAV still looks more like an execution trade than an easy long-term compounder.